A Study of Longer Interval of IVT IBI302 in Subjects With nAMD

Inclusion Criteria: 1. Willing and able to sign informed consent from and comply with visit and study procedures per protocol. 2. Male or female patients≥50 yrs. of age. 3. Active subfoveal or parafoveal CNV secondary to neovascular AMD on FFA or OCT. 4. The CNV area≥50% lesion area on FFA in the study eye at screening visit. 5. BCVA score of 24-78 letters using ETDRS charts in the study eye at the baseline. Exclusion Criteria: 1. Concomitant diseases that may cause subjects fail to respond to the treatment or confuse the interpretation of the study results. 2. Subretinal hemorrhage\>50% total lesion area and/or involvement in the macular foveal, fibrosis or atrophy area\>50% total lesion area and/or involved of macular fovea; 3. Presence of uncontrolled glaucoma in the study eye(defined as IOP≥25mmHg, or judged by the investigators at the screening or baseline visit) 4. Presence of active intraocular or periocular inflammation or infection; 5. Prior any treatment of following in the study eye: * Anti-VEGF(Vascular Endothelial Growth Factor) therapy or anti-complement therapy within 3 months prior to screening; * Laser photocoagulation within 3 months prior to screening; * Photodynamic therapy or vitreoretinal surgery; * Intraocular glucocorticoid injection within 6 months prior to enrollment; 6. Presence of any systemic disease: including but not limited tractive infections (such as active viral hepatitis); unstable angina; cerebrovascular accident or transient cerebral ischemia (within 6 months prior to selection); myocardial infarction (within 6 months prior to selection); serious arrhythmia requiring medical treatment; liver, kidney or metabolic diseases; or malignant tumor; 7. History of severe hypersensitivity/allergy to active ingredients or any excipients of the study drug, or fluorescein and povidone iodine; 8. Pregnant or lactating women or women preparing to become pregnant or breastfeeding during the study period; 9. Participated in any clinical study of any other drug within three months prior to enrollment, or attempted to participate in other drug trials during the study; 10. Other conditions unsuitable for enrollment judged by investigators